Keynote address: 'No time to lose: of infectious diseases, science, politics and institutions’, Prof. Peter Piot, London School of Hygiene and Tropical Medicine, UK (ESCAIDE 2013)
•Download as PPTX, PDF•
2 likes•782 views
Presentation from the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), published by the European Centre for Disease Prevention and Control (ECDC)
Recommended
More Related Content
What's hot
What's hot (19)
Viewers also liked
Viewers also liked (14)
Similar to Keynote address: 'No time to lose: of infectious diseases, science, politics and institutions’, Prof. Peter Piot, London School of Hygiene and Tropical Medicine, UK (ESCAIDE 2013)
Similar to Keynote address: 'No time to lose: of infectious diseases, science, politics and institutions’, Prof. Peter Piot, London School of Hygiene and Tropical Medicine, UK (ESCAIDE 2013) (20)
More from European Centre for Disease Prevention and Control
More from European Centre for Disease Prevention and Control (20)
Recently uploaded
Recently uploaded (20)
Keynote address: 'No time to lose: of infectious diseases, science, politics and institutions’, Prof. Peter Piot, London School of Hygiene and Tropical Medicine, UK (ESCAIDE 2013)
- 1. No Time to Lose: Of infectious disease, science, politics and institutions Peter Piot ESCAIDE Stockholm 5.11.2013 Improving health worldwide www.lshtm.ac.uk
- 5. My lessons from Ebola, 1976 • Time , place, person! • Poverty driving disease • The power and challenges of international collaboration • EIS : US field epidemiology • Good intentions can be dangerous
- 9. Global HIV prevalence in adults, 1985 UNAIDS/WHO, 2006
- 10. Prevalence of HIV Infection,2012 Piot and Quinn, N Engl J Med 2013; 368:2210
- 12. Lessons from STD and HIV research • The power of combining epidemiology with clinical and laboratory sciences • Pre-eminence of social determinants, economics, politics and human rights • Opportunities and challenges of international collaboration • Europe needs a CDC • Weak EU support for global health research
- 15. Non-viral resistance • Experts: in public health and health services, essential medicines, international development • Institutions: development agencies, World Bank, European Commission, WHO, Unicef • Politicians: Ministers of Health and of Finance • Denial about HIV : e.g. President Mbeki • Lack of ambition
- 16. “the brutal fact was that those who could pay for Africa’s AIDS therapy - the pharmaceutical industry by way of price cuts, and rich-country tax payers by way of foreign aid – are very unlikely ... to do so” (W McGreevy, World Bank,1998)
- 17. Treatment Action Campaign (TAC)
- 18. Leadership Former President Fernando Henrique Cardoso of Brazil. 1988 Drugs for opportunistic infections provided 1991 Zidovudine provided 1996 Free and widespread distribution of ARV
- 19. UN Secretary- General Kofi Annan, Al Gore, Vice President of the USA, chaired the first debate on AIDS as a major security issue at the UN Security Council in January 2000. UN Photo
- 20. Prices (US$/year) of antiretroviral regimen in Uganda: 1998-2003
- 21. UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON HIV/AIDS 25 - 27 JUNE2001 United Nations
- 23. Resources available for HIV in low- and middle-income UNAIDS Source: UNAIDS, 2010 23 October 14, 2014 countries, 1986-2010
- 25. People on ART in low and middle income countries (UNAIDS,2012)
- 27. Lessons from the AIDS response • Evidence: both size of the problem and of solutions • Human rights as driver • Unified strategy • Political strategy • Bring solutions • A brilliant coalition • Activism by people affected • Never take no for an answer!
- 29. Lessons from the chameleon • Focus on your goal • Be flexible, while sticking to goal • Constantly process intelligence • One step at a time • Timing is everything
- 30. How AIDS invented Global Health (A.Brandt, NEJM 2013) • Disrupted divide between prevention and treatment • New forms of disease advocacy and activism • New global funding • Changed the cost of essential medicines • Recognised basic human rights • Major boost for global health research and academic interest
- 31. • •
- 32. HIV incidence and deaths England, 1981-2010 (PHE,2012)
- 33. New HIV infections 2001-2012
- 34. In some countries the entire AIDS treatment budget comes from international sources Percentage of care and treatment expenditure from international sources 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Democratic Republic of the Congo Rwanda Central African Republic Niger Eritrea Malawi Guinea-Bissau Mozambique Guinea Mali Cote d'Ivoire Nigeria Sierra Leone Burkina Faso Kenya Togo Ghana Burundi Uganda Cameroon Swaziland Senegal Benin Gabon Chad Angola Morocco Lesotho Botswana Congo Egypt Seychelles Algeria
- 36. Efficacy of primary and secondary ARV-based TDF-2 FTC/TDF 63% (22; 83) iPrEx FTC/TDF 42% (15; 63) 0% 10 20 30 40 50 60 70 80 90 100% Partners PrEP FTC/TDF Partners PrEP TDF 73% (49; 85) CAPRISA 004 TNF gel 39% (6; 60) FEM PrEP FTC/TDF 0% (-69; 41) prevention studies 62% (34; 78) VOICE TDF 96% (77; 99) HPTN 052
- 37. 100 80 60 40 20 0 Percent The HIV Treatment Cascade Piot and Quinn, NEJM 2013; United States Mozambique
- 39. How well equipped is Europe for the next challenges? • New health challenges will emerge • Many countries have weak institutional capacity • Financial crisis has weakened Europe’s public health and response capacity • Challenges beyond infectious diseases • Use regional funds to strengthen public health institutions • Need to expand mandate of ECDC
- 41. Declan B. Polio risk looms over Europe. Nature 2013; 502: 601
- 42. Europe needs a strong, autonomous Centre for Disease Control and Prevention , working with strong autonomous national Centres, addressing both infectious and chronic diseases
- 43. Science Empowerment Development Politics Services